Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.

Prostate Cancer · 2022 · PMC9534720 · PMID 36212187

Europe PMC DOI

hedged sentence

0.1960

closest p · 3.9× alpha

0.1960

boldest claim

The sentences

did not reach statistical significanceP =0.196not close (p > 0.1)

Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23–1.36, P =0.196); time to testosterone recovery was similar in the ADT-containing groups.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.